Therefore, our data showed that MMP9 hepatic mRNA levels could be used earlier as a prognostic marker to identify NASH patients whose disease could progress to cirrhosis and HCC. The gene discussed is MMP9; the disease is metabolic dysfunction-associated steatohepatitis.